We are live on ! Find out more
RCP

Rho Capital Partners Portfolio holdings

AUM $20.4M
This Fund
S&P 500
This Quarter Est. Return
-12.89%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$71.6M
AUM Growth
+$461K
Cap. Flow
+$11.3M
Cap. Flow %
15.8%
Top 10 Hldgs %
100%
Holding
4
New
1
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
MRSN
Mersana Therapeutics
MRSN
+$11.3M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVRD
1
Tvardi Therapeutics
TVRD
$24M
$54.9M 76.67%
99,113
– –
MRSN
2
DELISTED
Mersana Therapeutics
MRSN
$11.4M 15.96%
+32,721
New +$11.3M
RCKT icon
3
Rocket Pharmaceuticals
RCKT
$358M
$4.99M 6.97%
656,948
– –
SENS icon
4
Senseonics Holdings Inc
SENS
$254M
$287K 0.4%
7,980
– –

Similar funds

LUGPI
Lightspeed Ultimate General Partner IX Menlo Park, California $20.3M AUM 4.78% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
SIC
Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return
DOS
David O. Sacks $19.8M AUM 4.02% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return
CVSCT
C.V. Starr & Co Trust New York $19.4M AUM 28.57% 1-Year Est. Return
VNB
Virginia National Bank Charlottesville, Virginia $21.9M AUM 12.04% 1-Year Est. Return
BEP
Brookside Equity Partners Stamford, Connecticut $22.5M AUM 62.43% 1-Year Est. Return

Rho Capital Partners's Q2 2017 Portfolio in Review

As of Q2 2017, Rho Capital Partners held 4 positions worth $71.6M, up 0.65% from $71.2M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Rho Capital Partners deployed $11.3M of net new capital in Q2 2017, opening 1 new position. Its largest new stake was Mersana Therapeutics: 32,721 shares worth $11.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Rho Capital Partners's largest Q2 2017 buy was Mersana Therapeutics: 32,721 shares worth $11.4M.
  • Rho Capital Partners's ten largest holdings make up 100% of its $71.6M portfolio in Q2 2017.
  • Rho Capital Partners opened 1 new position and closed 0 in Q2 2017.
  • Rho Capital Partners's portfolio value rose 0.65% quarter-over-quarter to $71.6M.

Based on Rho Capital Partners's 13F filing for Q2 2017, filed 7 Aug 2017.